Is Lacosamide Approved or Used for Hypertension?
No, lacosamide is not approved or indicated for managing hypertension, including cases secondary to other conditions like pheochromocytoma, renal disease, or endocrine disorders. It is an anticonvulsant primarily approved for partial-onset seizures in epilepsy, acting via selective slow inactivation of voltage-gated sodium channels.[1]
What Is Lacosamide's Actual Role?
Lacosamide (brand name Vimpat) treats epilepsy in adults and children aged 4 and older. It stabilizes neuronal membranes by enhancing slow sodium channel inactivation, reducing abnormal brain electrical activity. The FDA and EMA approvals limit its use to seizure control; no cardiovascular indications exist.[1][2]
Why Not for Hypertension?
Hypertension requires blood pressure-lowering agents like ACE inhibitors, beta-blockers, or calcium channel blockers, which target vascular tone, renin-angiotensin systems, or sympathetic activity. Lacosamide lacks these mechanisms. Preclinical studies show no significant antihypertensive effects; it may even cause minor heart rate changes or PR interval prolongation unrelated to blood pressure reduction.[3]
Any Off-Label or Investigational Use for Blood Pressure?
No clinical trials, guidelines, or case reports support off-label use of lacosamide for hypertension. Searches of PubMed, ClinicalTrials.gov, and pharmacology databases yield zero relevant studies. Its sodium channel effects could theoretically worsen arrhythmias in hypertensive patients with heart conditions, not help.[4]
Risks of Using It for Hypertension
Attempting lacosamide for blood pressure control risks inadequate treatment of hypertension (leading to stroke or heart failure) plus drug-specific side effects: dizziness (30% of patients), nausea (15-20%), and cardiac conduction issues (up to 10%). Drug interactions with antihypertensives are unstudied and potentially hazardous.[1][3]
Alternatives for Secondary Hypertension
Management depends on the underlying cause:
- Pheochromocytoma: Alpha-blockers (phenoxybenzamine) followed by beta-blockers.
- Renal artery stenosis: ACE inhibitors or angioplasty.
- Hyperaldosteronism: Spironolactone.
Consult guidelines from the American Heart Association for tailored therapy.[5]
Sources
[1]: FDA Label for Vimpat (lacosamide)
[2]: EMA Summary for Lacosamide
[3]: Lacosamide Pharmacology Review, DrugBank
[4]: PubMed Search: "lacosamide hypertension" (0 results)
[5]: AHA 2017 Hypertension Guidelines